CDX2 and colorectal cancer: Similar to CDX2 expression in colorectal cancer,4, 20 we found in our present study that patients with loss of CDX2 expression tumors had poor clinical outcomes in the absence of systemic therapy, but many of them benefited greatly from postoperative adjuvant chemotherapy; despite better prognosis, patients with CDX2‐positive tumors were far less sensitive to systemic chemotherapy and patients with CDX2‐positive tumors did not benefit from adjuvant chemotherapy.